Literature DB >> 20838788

Comparative analysis of mutation of tyrosine kinase kit in mast cells from patients with systemic mast cell activation syndrome and healthy subjects.

Gerhard J Molderings1, Kirsten Meis, Ulrich W Kolck, Jürgen Homann, Thomas Frieling.   

Abstract

Systemic mast cell activation syndrome is a mast cell disorder characterized by an unregulated increased activation of mast cells leading to a pathologically enhanced release of mediators. Mutations in tyrosine kinase kit which crucially determines mast cell activity have been suggested as a necessary condition for the development of a clinically symptomatic mast cell disease. At the level of mRNA in mast cell progenitor cells of 20 patients with systemic mast cell activation syndrome and of 20 gender- and age-matched healthy volunteers, the tyrosine kinase kit was investigated for genetic alterations by means of RT-PCR and direct sequencing of the amplificates. In mast cells of 13 out of these 20 patients, multiple predominantly novel potential functionally activating point mutations or complex alterations of the mRNA sequence encoding the tyrosine kinase kit were detected. In contrast, in 19 of the 20 healthy subjects, no functionally relevant alterations of c-kit transcripts were detected. The present findings support the idea that the systemic mast cell activation syndrome is a clonal disease most commonly associated with variable activating mutations in the tyrosine kinase kit.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20838788     DOI: 10.1007/s00251-010-0474-8

Source DB:  PubMed          Journal:  Immunogenetics        ISSN: 0093-7711            Impact factor:   2.846


  34 in total

1.  Response of a KIT-positive extra-abdominal fibromatosis to imatinib mesylate and KIT genetic analysis.

Authors:  Anthony Gonçalves; Genevieve Monges; Ying Yang; Fabienne Palmerini; Patrice Dubreuil; Tetsuro Noguchi; Jocelyne Jacquemier; Donatella Di Stefano; Jean-Robert Delpero; Hagay Sobol; Francois Bertucci
Journal:  J Natl Cancer Inst       Date:  2006-04-19       Impact factor: 13.506

2.  Abnormality of c-kit oncoprotein in certain patients with chronic myelogenous leukemia--potential clinical significance.

Authors:  K Inokuchi; H Yamaguchi; M Tarusawa; M Futaki; H Hanawa; S Tanosaki; K Dan
Journal:  Leukemia       Date:  2002-02       Impact factor: 11.528

3.  Identification of a polymorphism in the transmembrane domain of the protooncogene c-kit in healthy subjects.

Authors:  H Nagata; A S Worobec; D D Metcalfe
Journal:  Exp Clin Immunogenet       Date:  1996

4.  Molecular correlates of imatinib resistance in gastrointestinal stromal tumors.

Authors:  Michael C Heinrich; Christopher L Corless; Charles D Blanke; George D Demetri; Heikki Joensuu; Peter J Roberts; Burton L Eisenberg; Margaret von Mehren; Christopher D M Fletcher; Katrin Sandau; Karen McDougall; Wen-bin Ou; Chang-Jie Chen; Jonathan A Fletcher
Journal:  J Clin Oncol       Date:  2006-09-05       Impact factor: 44.544

5.  Mutation analysis of C-KIT in patients with myelodysplastic syndromes without mastocytosis and cases of systemic mastocytosis.

Authors:  R Fritsche-Polanz; J H Jordan; A Feix; W R Sperr; G Sunder-Plassmann; P Valent; M Födinger
Journal:  Br J Haematol       Date:  2001-05       Impact factor: 6.998

6.  Mechanisms of oncogenic KIT signal transduction in primary gastrointestinal stromal tumors (GISTs).

Authors:  Anette Duensing; Fabiola Medeiros; Bryna McConarty; Nora E Joseph; Dipak Panigrahy; Samuel Singer; Christopher D M Fletcher; George D Demetri; Jonathan A Fletcher
Journal:  Oncogene       Date:  2004-05-13       Impact factor: 9.867

7.  Association of paediatric mastocytosis with a polymorphism resulting in an amino acid substitution (M541L) in the transmembrane domain of c-KIT.

Authors:  R Foster; E Byrnes; C Meldrum; R Griffith; G Ross; E Upjohn; A Braue; R Scott; G Varigos; P Ferrao; L K Ashman
Journal:  Br J Dermatol       Date:  2008-09-15       Impact factor: 9.302

8.  Structural basis for activation of the receptor tyrosine kinase KIT by stem cell factor.

Authors:  Satoru Yuzawa; Yarden Opatowsky; Zhongtao Zhang; Valsan Mandiyan; Irit Lax; Joseph Schlessinger
Journal:  Cell       Date:  2007-07-27       Impact factor: 41.582

Review 9.  Recent advances in the understanding of mastocytosis: the role of KIT mutations.

Authors:  Alberto Orfao; Andrés C Garcia-Montero; Laura Sanchez; Luis Escribano
Journal:  Br J Haematol       Date:  2007-07       Impact factor: 6.998

10.  Unique effects of KIT D816V in BaF3 cells: induction of cluster formation, histamine synthesis, and early mast cell differentiation antigens.

Authors:  Matthias Mayerhofer; Karoline V Gleixner; Andrea Hoelbl; Stefan Florian; Gregor Hoermann; Karl J Aichberger; Martin Bilban; Harald Esterbauer; Maria-Theresa Krauth; Wolfgang R Sperr; Jack B Longley; Robert Kralovics; Richard Moriggl; Jacques Zappulla; Roland S Liblau; Ilse Schwarzinger; Veronika Sexl; Christian Sillaber; Peter Valent
Journal:  J Immunol       Date:  2008-04-15       Impact factor: 5.422

View more
  19 in total

1.  A 60-year-old woman with recurrent episodes of flushing, urticaria, and angioedema.

Authors:  Sheenal V Patel; James L Baldwin
Journal:  Allergy Asthma Proc       Date:  2015 May-Jun       Impact factor: 2.587

2.  Mutational profiling in the peripheral blood leukocytes of patients with systemic mast cell activation syndrome using next-generation sequencing.

Authors:  Janine Altmüller; Britta Haenisch; Amit Kawalia; Markus Menzen; Markus M Nöthen; Heide Fier; Gerhard J Molderings
Journal:  Immunogenetics       Date:  2017-04-06       Impact factor: 2.846

Review 3.  Systemic mast cell activation disease: the role of molecular genetic alterations in pathogenesis, heritability and diagnostics.

Authors:  Britta Haenisch; Markus M Nöthen; Gerhard J Molderings
Journal:  Immunology       Date:  2012-11       Impact factor: 7.397

Review 4.  Anaphylaxis as a clinical manifestation of clonal mast cell disorders.

Authors:  A Matito; I Alvarez-Twose; J M Morgado; L Sánchez-Muñoz; A Orfao; L Escribano
Journal:  Curr Allergy Asthma Rep       Date:  2014-08       Impact factor: 4.806

5.  Evidence for contribution of epigenetic mechanisms in the pathogenesis of systemic mast cell activation disease.

Authors:  Britta Haenisch; Holger Fröhlich; Stefan Herms; Gerhard J Molderings
Journal:  Immunogenetics       Date:  2014-03-14       Impact factor: 2.846

Review 6.  Immunology and clinical manifestations of non-clonal mast cell activation syndrome.

Authors:  Juan-Carlos Cardet; Mariana C Castells; Matthew J Hamilton
Journal:  Curr Allergy Asthma Rep       Date:  2013-02       Impact factor: 4.806

Review 7.  Nonclonal Mast Cell Activation Syndrome: A Growing Body of Evidence.

Authors:  Matthew J Hamilton
Journal:  Immunol Allergy Clin North Am       Date:  2018-06-09       Impact factor: 3.479

Review 8.  Mast cell activation disease: a concise practical guide for diagnostic workup and therapeutic options.

Authors:  Gerhard J Molderings; Stefan Brettner; Jürgen Homann; Lawrence B Afrin
Journal:  J Hematol Oncol       Date:  2011-03-22       Impact factor: 17.388

Review 9.  Mast Cell-Mediated Mechanisms of Nociception.

Authors:  Anupam Aich; Lawrence B Afrin; Kalpna Gupta
Journal:  Int J Mol Sci       Date:  2015-12-04       Impact factor: 5.923

10.  A subset of gastrointestinal stromal tumors previously regarded as wild-type tumors carries somatic activating mutations in KIT exon 8 (p.D419del).

Authors:  Sebastian Huss; Helen Künstlinger; Eva Wardelmann; Michaela A Kleine; Elke Binot; Sabine Merkelbach-Bruse; Thomas Rüdiger; Jens Mittler; Wolfgang Hartmann; Reinhard Büttner; Hans-Ulrich Schildhaus
Journal:  Mod Pathol       Date:  2013-04-19       Impact factor: 7.842

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.